user

Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis

被引：0
|
作者：
Clélia Monchablon
Henri Gondé
Sophie Pouplin
Rémi Varin
Olivier Vittecoq
Thierry Lequerré
机构：
[1] Rouen University Hospital,Department of Pharmacy
[2] Rouen University Hospital,Normandie Univ, UNIROUEN, U1234 Inserm, Department of Pharmacy
[3] Rouen University Hospital,Department of Rheumatology
[4] Rouen University Hospital,Normandie Univ, UNIROUEN, U1234 Inserm, Department of Rheumatology
来源：
Clinical Rheumatology | 2020年 / 39卷
关键词：
Adherence; Medication; Questionnaire; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：207 / 216
页数：9
相关论文
共 50 条
  • [31] TIMING OF PNEUMOCOCCAL VACCINATIONS IN RELATION TO STARTING DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Costello, R. E.
    Humphreys, J.
    Winthrop, K.
    Dixon, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 961 - 962
  • [32] THE IMPACT OF EDUCATION ON ADHERENCE TO TREATMENT WITH DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS
    Holc, I.
    Pahor, A.
    Gradisnik, S.
    Dai, K.
    Krajnc, M. Koren
    Grobelsek, V. Kovacic
    Dobnik, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 706 - 707
  • [33] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [34] Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis
    Garrood, T
    Scott, DL
    BIODRUGS, 2001, 15 (08) : 543 - 561
  • [35] Combination Therapy with Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
    Toby Garrood
    David L. Scott
    BioDrugs, 2001, 15 : 543 - 561
  • [36] Medication adherence in rheumatoid arthritis patients treated with biological disease-modifying anti rheumatic drugs
    Joensuu, J. T.
    Aaltonen, K. J.
    Valleala, H.
    Puolakka, K.
    Yli-Kerttula, T.
    Varjolahti-Lehtinen, T.
    Sokka, T.
    Blom, M.
    Nordstrom, D.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 (05) : 434 - 434
  • [37] Is cholecalciferol a potential disease-modifying anti-rheumatic drug for the management of rheumatoid arthritis?
    Bellan, M.
    Andreoli, L.
    Nerviani, A.
    Piantoni, S.
    Avanzi, G. C.
    Soddu, D.
    Hayden, E.
    Pirisi, M.
    Sainaghi, P. P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (02) : 343 - 349
  • [38] The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients
    Shahabi, Ahva
    Shafrin, Jason
    Zhao, Lauren
    Green, Sarah
    Curtice, Tammy
    Marshall, Alexander
    Paul, Damemarie
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 350 - 358
  • [39] A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
    Sen, Rouhin
    Riofrio, Maria
    Singh, Jasvinder A.
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (06) : 687 - 714
  • [40] IMMUNOGENICITY OF SUBCUTANEOUS AND INTRAVENOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Genovese, Mark C.
    Ogata, Atsushi
    Nomura, Akira
    Bao, Min
    Hitraya, Elena
    Lacey, Stuart
    Burmester, Gerd R.
    RHEUMATOLOGY, 2016, 55 : 92 - 93
12345